Key Highlights:
- Nearly €8 million invested in Archet 2’s infrastructure, aiming to improve healthcare services and the well-being of patients and staff.
- Specific modernization of the pediatric department with €3.41 million for family-optimized individual rooms.
- Allocation of €4.46 million to the medical genetics department for its modernization and relocation, consolidating its status as a reference center for rare diseases.
The Nice University Hospital, with Archet 2 as its flagship, inaugurates a new era in the field of health on the Côte d’Azur, thanks to a substantial investment of nearly €8 million. This initiative reflects an ambitious strategy to reinvent the standards of hospital care and medical treatment.
Renovation Focused on Patients and Research
The €3.41 million envelope dedicated to the pediatric department marks a shift towards a more humane and reassuring hospitalization for children and their families. The transformation has made it possible to set up individual rooms with all the necessary amenities, promoting a secure environment for young patients.
The pediatric oncohematology department is thus equipped with a renovated space capable of effectively meeting the complex needs of treatments and follow-up of serious illnesses in children.
Medical Genetics Department, a Pillar of Innovation
The €4.46 million investment allocated to the medical genetics department reflects a desire to position Archet 2 as a leader in the treatment and research of rare diseases. This department strengthens its ability to offer cutting-edge care and to collaborate with national and international networks specialized in rare genetic diseases.
These renovations embody a vision of the future where the quality of care and patient comfort are priorities. The investment that Archet 2 is benefiting from is not just a financial commitment; it symbolizes an approach resolutely focused on medical excellence and respect for the human being in the care pathway.
Health Nice Côte d’Azur
- Exceptional dynamics in the first half of 2024 for Virbac
- Virbac announces changes in its executive management
- Virbac finalizes acquisition of minority stake in Globion, Indian poultry vaccine specialist.
- Christophe Mossé appointed as CEO of Arkopharma group
- Nucleate France UniCA strengthens the ties between research, industry, and entrepreneurship in life sciences.
- Business Landing Nice Côte d’Azur: Support for business set up in France
- Biotyks sets up in Nice to develop its solution for managing irritable bowel syndrome
- The Climate and Biodiversity Tour in Nice
- Team Nice Côte d’Azur in force at Viva Tech 2024
- Entrepreneurship in Research Award 2024
